Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination
Duran-Castells, Clara (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Prats, Anna (Institut Germans Trias i Pujol. Fundació Lluita Contra les Infeccions)
Oriol-Tordera, Bruna (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Llano Montero, Anuska (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Gálvez, Cristina (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Muñoz-Moreno, Jose A. (Institut Germans Trias i Pujol. Fundació Lluita Contra les Infeccions)
Hanke, Thomas (University of Oxford. The Jenner Institute)
Moltó, José (Institut Germans Trias i Pujol. Fundació Lluita Contra les Infeccions)
Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Brander, Christian (Universitat Autònoma de Barcelona. Departament de Medicina)
Ruiz Riol, Marta (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)

Date:	2023
Abstract:	Biomarkers predicting the outcome of HIV-1 virus control in natural infection and after therapeutic interventions in HIV-1 cure trials remain poorly defined. The BCN02 trial (NCT02616874), combined a T-cell vaccine with romidepsin (RMD), a cancer-drug that was used to promote HIV-1 latency reversal and which has also been shown to have beneficial effects on neurofunction. We conducted longitudinal plasma proteomics analyses in trial participants to define biomarkers associated with virus control during monitored antiretroviral pause (MAP) and to identify novel therapeutic targets that can improve future cure strategies. BCN02 was a phase I, open-label, single-arm clinical trial in early-treated, HIV infected individuals. Longitudinal plasma proteomes were analyzed in 11 BCN02 participants, including 8 participants that showed a rapid HIV-1 plasma rebound during a monitored antiretroviral pause (MAP-NC, 'non-controllers') and 3 that remained off ART with sustained plasma viremia <2000 copies/ml (MAP-C, 'controllers'). Inflammatory and neurological proteomes in plasma were evaluated and integration data analysis (viral and neurocognitive parameters) was performed. Validation studies were conducted in a cohort of untreated HIV-1+ individuals (n = 96) and in vitro viral replication assays using an anti-CD33 antibody were used for functional validation.
Grants:	Ministerio de Ciencia e Innovación SAF2017-89726-R Ministerio de Ciencia e Innovación PID2020-119710RB-I00 European Commission GA101057548
Note:	Altres ajuts: National Institutes of Health (NIH), P01-AI131568
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Control of HIV-1 infection ; Plasma proteomics ; Inflammation ; Neurological function ; Siglec-3/CD33 ; Kick and kill HIV cure strategy
Published in:	EBioMedicine, Vol. 95 (september 2023) , ISSN 2352-3964

DOI: 10.1016/j.ebiom.2023.104732
PMID: 37506557

15 p, 2.7 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles